Intra-cellular Therapies, Inc.

Mitokor, Inc.

Acadia Pharmaceuticals Inc.

Geodynamics, Inc.

Migenix, Inc.

Cp Manufacturing, Inc.

Snap-on Inc.

Cape Analytics, Inc.

Kalypsys, Inc.

Treehouse Biotech, Inc.

Other

University of California

Fmc Corporation

Molycorp, Inc.

Smith & Loveless Inc.

Robert E Davis

Peng Li

Lawrence P Wennogle

Sharon Mates

Kimberly Vanover

Mark R Brann

David M Weiner

Soumitra S Ghosh

Carl-Magnus A Andersson

Allan K Uldam

Gretchen Snyder

Qiang Zhang

Wei Yao

Christen M Anderson

William Christensen Clevenger

Corinna Herrnstadt

Sandra Eileen Wiley

Walter H Moos

Scott W Miller

Tomas R Szabo

John Thomas Hardesty

Shelby Lee Sullivan

Yazhong Pei

David S Wesson

Hailin Zheng

Timothy G Ruther

Terrell Saltarelli

Nicholas Davis

Joseph Hendrick

Eoin D Fahy

Kevin R George

Stewart Alwyn Noble

John Charles Tomesch

Allen Borchardt

Michael D Wroblicky

John S Kiely

John L Burba, Iii

James W Malecha

Mehmet Kahraman

Gonul Velicelebi

Ernest L Baker

Frank G Weis

Johnny Joslin

Anne N Murphy

Jason Ansley

Michel B Alberry

Anthony J Cichy

Jeremy Castaneda

Wayne O Rosenthal

Jacob Black

Giacomo Vianello

Alexander Y Andreyev

Luciano G Frigeri

Toru Hashimoto

David Kass

Mark Hooper

John K Clark

Norman Nash

Jonathan M Fisher

Sean Colvin

Graham Buckton

Thomas Smeltzer

Abbas Haider

Aaron Holmberg

Yuhei Yamamoto

Allen Fienberg

Takashi Abe

Arthur Daniels

Hideaki Maruyama

James Douglas Weller

David Charles Daniel

Michael T DeKeuster

James A Dykens

Jennifer O'Brien

William Paul Findlay

Robert Terkeltaub

Hironori Yamashita

Christopher J Hockett

Sophie Dutheil

Yupu Qiao

Thomas G Seador

John Evanyo

Robert Michael Romano

Daniel Isaac Armstrong

Daniel Edgar Nelson

Masahiro Takasuga

Allan K Uldan

Gonul Velecelebi

Anna-Maria Frost-Jensen, Legal Representative

Andrew E Granston, Jr

Michael T Dekeuster

Shelby I Sullivan

Richard A Lerner

MDavid Weiner

The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HTreceptor, the serotonin transporter (SERT), pathways involving the dopamine Dand Dreceptor signaling system, and/or the μ-opioid receptor.

Organic compounds

The disclosure provides methods the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and for treatment of psychiatric symptoms of viral, bacterial, and autoimmune encephalitis, and for protecting or reinforcing the blood-brain barrier, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT.

Methods

The present invention relates to PDE1 inhibitory compounds useful in the treatment of diseases involving disorders of the dopamine D1 receptor intracellular pathway, such as, among others, Parkinson's disease, depression, narcolepsy, psychosis, damage to cognitive function, e.g., in schizophrenia, or disorders that may be ameliorated through enhanced progesterone-signaling pathway, as well as their use as pharmaceuticals and pharmaceutical compositions comprising them. Methods of making and methods of use related to such compounds are further described.

Compounds

The disclosure provides methods for the acute treatment of depression and/or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A or 5-HT2A/D2 receptor ligand, e.g. lumateperone.

Methods of treating acute depression

The invention relates to pharmaceutical compositions comprising the compound of Formula I, and new methods and uses pertaining thereto, and pharmaceutical compositions thereof, such as methods of use in the treatment of diseases involving the 5-HT receptor, the serotonin transporter (SERT), and/or pathways involving dopamine Dreceptor signaling, sodium channel activity, and/or norepinephrine transporter activity.

Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders

The disclosure relates to the use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of cancers and tumors, including for inhibiting tumor recruitment of macrophages and other cells to the tumor or cancer, for complementing and enhancing checkpoint inhibitor therapies, and for mitigating the side effects (i.e., inflammatory-related adverse events) associated with checkpoint inhibitor therapies.

The disclosure provides the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and prophylaxis of diseases or disorders characterized by inflammation, including methods of treatment and pharmaceutical compositions for use therein.

Methods of treating inflammatory disease

The invention relates to particular deuterated substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HTreceptor, the serotonin transporter (SERT), pathways involving the dopamine Dand Dreceptor signaling system, and/or the μ-opioid receptor.

The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.

Transmucosal methods for treating psychiatric and neurological conditions

The invention relates to particular prodrugs and analogs of (3α,5α)-3-hydroxy-21-(1H-imidazol-1-yl)-3-methoxymethyl)-pregnan-20-one, in free or pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use as sedatives, hypnotics, anxiolytics, and/or anesthetics, and methods for treatment of depression, anxiety, insomnia, epilepsy, and other central nervous system disorders, as well as to combinations with other agents.

In variants, the method for automatic debris detection includes: determining a region image; optionally determining a parcel representation for the region image; generating a debris representation using the region image; generating a debris score based on the debris representation; and optionally monitoring the debris score over time.

Method and system for automated debris detection

This invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HTreceptor, serotonin transporter (SERT) and/or pathways involving dopamine D/Dreceptor signaling systems, and/or the treatment of residual symptoms.

The invention relates to pharmaceutical compositions comprising compounds of Formula Q: wherein W is —N(CH)—, and Y is —C(O)—, in free base or pharmaceutically acceptable salt form, and methods of use in the treatment of diseases involving 5-HTreceptor, serotonin transporter (SERT) pathway and/or the dopamine Dreceptor pathway, and methods of treating conditions of the central nervous system therewith.

Pharmaceutical compositions comprising 4-((6bR, 10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)butan-1-one for treating central nervous system disorders

A quick-release latch may include a male component and a female component. The male component may include an insertable male portion comprising a top wall, a bottom wall, and one or more sidewalls. The male component may also include a first strap attachment portion defining a first plurality of strap openings each having a laterally extending strap slot and a mouth positioned off-center of and providing exterior access to the respective strap slot. The female component may include a female receptacle portion comprising a top wall, a bottom wall, and one or more sidewalls collectively forming a receptacle configured to receive and releasably lock to the insertable male portion of the male component. The top wall of the female receptacle may include a cantilever wall partially surrounded by one or more slots. The cantilever wall may extend proximate a same plane as the top wall.

Quick-release latches

Growing community of inventors

San Diego, CA, United States of America

Robert E Davis